drugset / Trial / NCT06890611
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Timeline
- Start
- 2025-03-25
- Primary completion
- 2025-09-26
- Completion
- 2025-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimagrumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Tirzepatide | Peptide | — | Subcutaneous |
Indications
No indication recorded.